Price$9.65+3.32 (+52.45%)
2026-03-042026-06-05
News · 26 weeks54-46%
2025-12-142026-06-07
Mix2590d
- SEC Filings12(48%)
- Other7(28%)
- Insider3(12%)
- Analyst2(8%)
- Leadership1(4%)
Latest news
25 items- PRAnteris Advances Global PARADIGM Expansion with French Regulatory ClearanceMINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)) announced today that it has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the "PARADIGM Trial"). This authorization marks a significant milestone in the Company's clinical and regulatory strategy and enables patient recruitment to commence at leading centers in France. "Securing French regulatory clearance is an important step in the execution of th
- INSIDERDirector Knight Susan Elizabeth bought $102,228 worth of shares (11,000 units at $9.29) (SEC Form 4)4 - Anteris Technologies Global Corp. (0002011514) (Issuer)
- SECSEC Form 424B3 filed by Anteris Technologies Global Corp.424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECSEC Form 424B5 filed by Anteris Technologies Global Corp.424B5 - Anteris Technologies Global Corp. (0002011514) (Filer)
- INSIDERSEC Form 3 filed by new insider Knight Susan Elizabeth3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
- INSIDERNew insider Denaro Stephen claimed ownership of 23,722 shares (SEC Form 3)3 - Anteris Technologies Global Corp. (0002011514) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)
- PRAnteris Appoints Susan Knight and Stephen Denaro to its Board of DirectorsMINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced the appointment of Ms. Susan Knight and Mr. Stephen Denaro to serve on the Board of Directors (the "Board"). "On behalf of the management team and Board, I am delighted to welcome Sue to the Company," commented John Seaberg, Chairman of Anteris. "I am also delighted to welcome back Stephen, whose familiarity with our business and strong governance expertise make him a treme
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Leadership Update8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- PRAnteris Announces Results for the First Quarter of 2026MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. Q1 2026 Highlights Completed aggregate capital raises totalling $320 million in January 2026 to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR® THV SystemAdvanced PARADIGM Trial recruitment, supported by ongoing regula
- SECSEC Form 10-Q filed by Anteris Technologies Global Corp.10-Q - Anteris Technologies Global Corp. (0002011514) (Filer)
- PRAnteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM TrialMINNEAPOLIS and BRISBANE, Australia, May 05, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that the first patients in the United States have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve ("THV") global pivotal trial for patients with severe calcific aortic stenosis (the "PARADIGM Trial"). The procedures were performed by Azeem Latib, M.D. at Montefiore Medical Center, New York, United States. "Performing the first U.S. cas
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.SCHEDULE 13G/A - Anteris Technologies Global Corp. (0002011514) (Subject)
- SECSEC Form 424B3 filed by Anteris Technologies Global Corp.424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- PRAnteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM TrialMINNEAPOLIS and BRISBANE, Australia, April 28, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced it has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage policy. Eligible procedures performed at participating U.S. study sites are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32. The CMS framework oper
- SECSEC Form 424B3 filed by Anteris Technologies Global Corp.424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECAnteris Technologies Global Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECSEC Form 424B3 filed by Anteris Technologies Global Corp.424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)
- SECSEC Form EFFECT filed by Anteris Technologies Global Corp.EFFECT - Anteris Technologies Global Corp. (0002011514) (Filer)
- ANALYSTCantor Fitzgerald resumed coverage on Anteris Technologies Global Corp. with a new price targetCantor Fitzgerald resumed coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $15.00
- ANALYSTWells Fargo initiated coverage on Anteris Technologies Global Corp. with a new price targetWells Fargo initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $16.00
- SECSEC Form POS AM filed by Anteris Technologies Global Corp.POS AM - Anteris Technologies Global Corp. (0002011514) (Filer)
AVR FAQ
6 questionsWhere does AVR stock trade?
Anteris Technologies Global Corp. (AVR) is listed on NASDAQ.What sector and industry is AVR in?
Anteris Technologies Global Corp. operates in the Health Care sector, Industrial Specialties industry.When did Anteris Technologies Global Corp. go public?
Anteris Technologies Global Corp. (AVR) completed its IPO in 2024.What are analysts saying about AVR?
Anteris Technologies Global Corp. has had 6 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $1500.00 price target on 2026-03-12. Recent price targets range from $900.00 to $2200.00.What companies are similar to AVR?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare AVR side-by-side with any of them on Quantisnow.How can I track AVR on Quantisnow?
Quantisnow aggregates Anteris Technologies Global Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVR to receive live email and push alerts on every new disclosure.